January 19, 2016 · FLEMING | NOLEN | JEZ, L.L.P.
In recent studies and analysis, there has been some data suggesting that Viekira Pak, a hep C treatment from AbbVie Inc., may be the least safe option of the available leading treatments. The data also shows that it is associated with roughly $6.5 million in avoidable downstream medical expenses.
From January 2015 to October 2015, Advera Health filed seven separate Freedom of Information Act requests regarding event case reports involving Harvoni, Sovaldi, and Viekira Pak. The report showed more than 11,000 adverse events.
Viekira Pak has been associated with nausea, skin rash, itching, fatigue, and insomnia. Even worse yet is the possibility of liver damage.
Both Viekira Pak (with compensated cirrhosis) and Technivie (without cirrhosis) were developed as hep C treatments. The initial FDA approval was allegedly based on incomplete studies showing a 90% cure rate in hepatitis patients taking the treatment. Less than a year after the approval, the FDA issued warnings regarding Viekira Pak and Technivie.
The warning brought up the potential for significant damage to the liver, especially in those with existing conditions. This is an alarming concern that should raise red flags in all hep C patients taking these treatments.
At Fleming | Nolen | Jez, L.L.P., our team of Viekira Pak attorneys are determined to help individuals who have been harmed by either Viekira Pak or Technivie. We know that these supposed treatments are supposed to help hep C patients, not harm them further.
If you or someone you love has sustained serious liver damage connected with use of Viekira Pak or Technivie, contact our firm today. We are ready to help you file a claim and seek compensation from any damages you may have sustained. With our firm on your side, you can trust that your case is in great hands throughout the entire process.